1253 related articles for article (PubMed ID: 7946104)
1. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
[TBL] [Abstract][Full Text] [Related]
4. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
Metzger S; Hofmann H
Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
Menon T; Umamaheswari K; Kumarasamy N; Solomon S; Thyagarajan SP
Acta Trop; 2001 Oct; 80(2):151-4. PubMed ID: 11600094
[TBL] [Abstract][Full Text] [Related]
6. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons.
Sánchez-Vargas LO; Ortiz-López NG; Villar M; Moragues MD; Aguirre JM; Cashat-Cruz M; Lopez-Ribot JL; Gaitán-Cepeda LA; Quindós G
Rev Iberoam Micol; 2005 Jun; 22(2):83-92. PubMed ID: 16107165
[TBL] [Abstract][Full Text] [Related]
7. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Anil S; Ellepola AN; Samaranayake LP
J Oral Pathol Med; 2001 Sep; 30(8):481-8. PubMed ID: 11545239
[TBL] [Abstract][Full Text] [Related]
8. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
[TBL] [Abstract][Full Text] [Related]
9. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
Johnson EM; Warnock DW; Luker J; Porter SR; Scully C
J Antimicrob Chemother; 1995 Jan; 35(1):103-14. PubMed ID: 7768758
[TBL] [Abstract][Full Text] [Related]
10. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
11. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
12. The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon.
Ambe NF; Longdoh NA; Tebid P; Bobga TP; Nkfusai CN; Ngwa SB; Nsai FS; Cumber SN
Pan Afr Med J; 2020; 36():23. PubMed ID: 32774600
[TBL] [Abstract][Full Text] [Related]
13. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
White TC; Pfaller MA; Rinaldi MG; Smith J; Redding SW
Oral Dis; 1997 May; 3 Suppl 1():S102-9. PubMed ID: 9456667
[TBL] [Abstract][Full Text] [Related]
14. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
Cartledge JD; Midgley J; Gazzard BG
AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.
Sangeorzan JA; Bradley SF; He X; Zarins LT; Ridenour GL; Tiballi RN; Kauffman CA
Am J Med; 1994 Oct; 97(4):339-46. PubMed ID: 7942935
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
Samaranayake YH; Samaranayake LP; Tsang PC; Wong KH; Yeung KW
J Oral Pathol Med; 2001 Jul; 30(6):336-46. PubMed ID: 11459319
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant oral candidiasis in patients with HIV infection: a systematic review and meta-analysis.
Keyvanfar A; Najafiarab H; Talebian N; Tafti MF; Adeli G; Ghasemi Z; Tehrani S
BMC Infect Dis; 2024 May; 24(1):546. PubMed ID: 38822256
[TBL] [Abstract][Full Text] [Related]
20. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
Vazquez JA; Peng G; Sobel JD; Steele-Moore L; Schuman P; Holloway W; Neaton JD
Clin Infect Dis; 2001 Oct; 33(7):1069-75. PubMed ID: 11528582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
